• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Opko Health, Inc. (OPK)

    10.42 Down 0.01(0.10%) May 27, 4:03PM EDT
    ProfileGet Profile for:
    Opko Health, Inc.
    4400 Biscayne Boulevard
    Miami, FL 33137
    United States - Map
    Phone: 305-575-4100
    Website: http://www.opko.com

    Index Membership:N/A
    Full Time Employees:5,936

    Business Summary 

    OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States, Ireland, Chile, Spain, Israel, and Mexico. Its diagnostics business operates Bio-Reference Laboratories, a clinical laboratory that offers comprehensive laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units. The Bio-Reference Laboratories also provides core genetic testing and leverages products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s pharmaceutical segment features Rayaldee, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency and VARUBI for chemotherapy-induced nausea and vomiting. Its biologics business engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product under development for the treatment of growth hormone deficiency, and developing Factor VIIa drug for hemophilia using the carboxl terminal peptide technology. The company was incorporated in 1991 and is headquartered in Miami, Florida.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Opko Health, Inc.

    Corporate Governance 
    Opko Health, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 3; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Philip Frost M.D., Ph.D., 80
    Chairman and Chief Exec. Officer
    Dr. Jane H. Hsiao Ph.D., MBA, 69
    Vice Chairman and Chief Technical Officer
    Mr. Adam Logal , 38
    Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer
    Mr. Steven D. Rubin J.D., Esq., 56
    Exec. VP of Admin. and Director
    Ms. Kate Inman Esq., 43
    Deputy Gen. Counsel and Sec.
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders